Show All
How is Tourmaline Bio’s stock traded and when did it go public?
Tourmaline Bio’s stock is traded on the Nasdaq Capital Global Market under the symbol “TRML”. Tourmaline Bio went public via a reverse merger with Talaris Therapeutics, Inc. (TALS) on October 19, 2023, and began trading on a post-merger basis on October 20, 2023.
Where is Tourmaline Bio's corporate headquarters?
Tourmaline Bio’s headquarters are at 27 W 24th Street, Suite 702, New York, New York, 10010.
What is Tourmaline Bio’s fiscal year end?
Tourmaline Bio’s fiscal year end is December 31st.
Who is Tourmaline Bio’s transfer agent?
Tourmaline’s transfer agent is:
Computershare Trust Company N.A.
150 Royall Street
Canton, MA 02021
Toll-free Phone: 1-800-736-3001
International Phone: 1-781-575-3100
Who is Tourmaline Bio's auditor?
Tourmaline Bio’s auditor is Deloitte & Touche LLP
Who is Tourmaline Bio's legal counsel?
Tourmaline Bio’s legal counsel is Cooley LLP
Whom should I contact regarding investor inquiries?
Lee Stern by email: lstern@meruadvisors.com
Where can I download the applicable Form 8937s related to the merger with Talaris Therapeutics, Inc.?
Will you be declaring a dividend this year?
As we have disclosed in our SEC filings, we do not anticipate that we will pay any cash dividends in the foreseeable future. The current expectation is that we will retain our future earnings, if any, to fund the growth of our business as opposed to paying dividends.
